Migraine drug, rimegepant approved by EU with the brand name, Vydura (a/k/a Nurtec ODT in US): <br> <br> <a href="https://finance.yahoo.com/news/pfizer-biohaven-vydura-rimegepant-granted-104500600.html" rel="nofollow noopener noreferrer ugc" target="_blank">https://finance.yahoo.com/news/pfizer-biohaven-vydura-rimegepant-granted-104500600.html</a> <br> <br> PFE has the ex-US commercial rights to Vydura from a deal with BHVN struck in Nov 2021 (<a href="https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166695371" target="_blank">#msg-166695371</a>). The sales could be large enough to move the needle even for a company as large as PFE.